@prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix ns2: . @prefix ns1: . @prefix prov: . @prefix ns3: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { ns1:demonstrate . } sub:provenance { sub:assertion prov:generatedAtTime "2021-12-16T19:48:35.069491"^^xsd:dateTime; prov:wasGeneratedBy "S&T TWOC project version 2" . sub:version prov:value "2"^^xsd:integer . rdf:OBJECT rdfs:label "clinical efficacythrough randomized controlled trials ( RCTs ) in seriously ill patients" . rdf:OBJECT-POSITION rdfs:label "75"^^xsd:integer . rdf:PREDICATE rdfs:label "demonstrated" . rdf:PREDICATE-POSITION rdfs:label "[65]" . rdf:SUBJECT rdfs:label "only two treatments , remdesivir and dexamethasone" . rdf:SUBJECT-POSITION rdfs:label "36"^^xsd:integer . rdfs:ABSTRACT-UID ns2:50 "gvu30egy" . rdfs:SENTENCE rdfs:label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." . rdfs:TRIPLE-UID ns3:gvu30egy-TRIPLE-ABSTRACT-1 "gvu30egy-TRIPLE-ABSTRACT-1" . rdfs:label "dexamethasone" . rdfs:label "ill" . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB"; npx:hasSignature "Z8EId6cj8nGUMJTKfUevPKhw1ducJuokZwUeVsVpc7KxfCMVb/a3bckl6wqnPGZnT1dAuKwdCiEtyX1ofWfUV30/pnPlYTtTg/iiiCfi5GqgD2kH/VVH/FE7Ykiyqd29NsnJKEOmaLI24YDFZWAvvlc9kABl2TtSIkg2ZW6ujBI="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-12-16T19:48:35.069491"^^xsd:dateTime; prov:wasAttributedTo . }